Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CapsoVisionCV +1.86%12 Net Cash per Share is $0.07 as of Jun. 2026, which is 100% below its 10-year median of 63.78. GuruFocus rates CV with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 286 Medical Devices & Instruments companies, CapsoVision ranks worse than 94.41% on this metric.
CapsoVision (NAS:CV) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
CapsoVision Net Cash per Share Related Terms
CapsoVision Net Cash per Share Historical Data
* Premium members only.
The historical data trend for CapsoVision's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CV vs LAB, ELMD, CATX: Net Cash per Share Comparison
For the Medical Devices subindustry, CapsoVision's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CapsoVision Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CapsoVision's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where CapsoVision's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
CapsoVision's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CapsoVision (CV) has a Net Cash per Share of $0.07 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on CapsoVision and its competitors. This is 100% below median its historical median of 63.78. Over the past decade, CapsoVision's Net Cash per Share has ranged from 17.93 to 108.29. According to the industry distribution chart, CapsoVision ranks #270 out of 286 companies in the Medical Devices & Instruments industry, placing it in the top 94.4%.
Is CapsoVision's Net Cash per Share too high?
CapsoVision's current Net Cash per Share of $0.07 is 100% below median its 10-year median of 63.78. Over the past 10 years, this metric has ranged from a low of 17.93 to a high of 108.29. The Medical Devices & Instruments industry median Net Cash per Share is 9.42. CapsoVision's value of $0.07 is 99.3% below this industry median. Based on the distribution chart, CapsoVision ranks #270 out of 286 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CapsoVision has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CapsoVision's Net Cash per Share compare to LAB and ELMD?
According to the Medical Devices & Instruments industry distribution chart, CapsoVision ranks #270 out of 286 companies for Net Cash per Share. This places CapsoVision in the lower half of its industry. The industry median Net Cash per Share is 9.42. CapsoVision's value of $0.07 is 99.3% below this benchmark. Historically, CapsoVision's own Net Cash per Share has ranged from 17.93 to 108.29 over the past decade. While the company's 10-year median is 63.78 vs. the industry median of 9.42, CapsoVision has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.42, based on 286 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CapsoVision's current Net Cash per Share of $0.07 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on CapsoVision and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CapsoVision's current Net Cash per Share is $0.07, which is 100% below median its own 10-year median of 63.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CapsoVision stock overvalued right now?
CapsoVision (CV) has a current Net Cash per Share of $0.07. The current Net Cash per Share is $0.07, which is 100% below median its 10-year median of 63.78 and 99.3% below the Medical Devices & Instruments industry median of 9.42. CapsoVision's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For CapsoVision (CV), the current Net Cash per Share is $0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
12GF Score
Get the complete analysis for CV
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CV has been successfully added to your 
